Jubilant Ingrevia Finalizes Remidex Pharma Acquisition

Jubilant Ingrevia Limited announced the final completion of its acquisition of Remidex Pharma Private Limited. The transaction, valued at ₹16.5 crore, was finalized on March 30, 2026. Remidex Pharma, acquired for its expertise in micronutrient premixes and nutraceuticals, reported a turnover of ₹24.27 crore for the financial year ending March 31, 2025.

The company previously entered into a Share Purchase Agreement for Remidex Pharma for approximately ₹16.5 crore, with key terms initially disclosed on March 13, 2026. The acquisition covers 100% of Remidex Pharma's equity stake.

Strategic Boost for Nutrition and Pharma CMO

This acquisition is a strategic step for Jubilant Ingrevia to strengthen its pharmaceutical and nutraceutical operations. The company plans to leverage Remidex Pharma's manufacturing expertise in micronutrient premixes and contract manufacturing. This move is expected to enhance Jubilant's value chain, especially in human nutrition, complementing its existing leadership in vitamins. The addition of Remidex's facility in Bangalore also expands Jubilant's geographic footprint.

Remidex Pharma, founded in 1981 and based in Bangalore, operates as a contract manufacturing organization (CMO) for pharmaceutical and nutraceutical products. It holds key certifications such as WHO-GMP and ISO 9001:2015. For the financial year ending March 31, 2024, Remidex Pharma reported a turnover of ₹31.15 crore, followed by ₹24.27 crore in FY24-25. This acquisition supports Jubilant Ingrevia's growth strategy, focusing on both organic and inorganic expansion within its Nutrition and Specialty Chemicals segments.

Integration and Future Outlook

Following the acquisition, Jubilant Ingrevia now holds complete ownership of Remidex Pharma, which will operate as a wholly owned subsidiary. The combined entity is expected to offer more robust, integrated solutions in pharmaceutical manufacturing and nutraceutical production, with anticipated synergies from combining manufacturing infrastructure and client relationships.

Key areas to monitor include the successful integration of Remidex Pharma's operations and culture into Jubilant Ingrevia. The company will also need to navigate competitive market dynamics within the pharmaceutical and nutraceutical CMO space and maintain compliance with stringent regulatory standards.

As a point of scale, Jubilant Ingrevia reported a trailing twelve-month revenue of $484 million as of December 31, 2025. In the broader specialty chemicals sector where Jubilant Ingrevia operates, peers like Aarti Industries Ltd. and Deepak Nitrite Ltd. are also expanding capacities and portfolios in value-added segments. The nutraceutical ingredient sector itself presents strong attractiveness, despite fewer direct competitors.

Investors will likely track the progress of integrating Remidex Pharma's operations, its financial contribution to Jubilant Ingrevia's future results, and any new market or product developments stemming from the acquisition. Management commentary on achieving expected synergies will also be key.